+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Research Antibodies and Reagents Market by Product (Antibodies, Production, Source, Research Area), Technology (ELISA, Western Blot), Application, End User (Pharma, Academia) - Global Forecast to 2027

  • ID: 4986116
  • Report
  • December 2020
  • Region: Global
  • 272 Pages
  • Meticulous Market Research Pvt. Ltd.
The Global Research Antibodies and Reagents Market is Expected to Grow at a CAGR of 6% from 2019 to 2025 to Reach $14.56 Billion by 2025

FEATURED COMPANIES

  • BioLegend Inc. (U.S.)
  • GE Healthcare (U.S.)
  • Johnson & Johnson (U.S.)
  • Lonza (Switzerland)
  • Merck KGaA (Germany)
  • PerkinElmer Inc. (U.S.)
The research antibodies and reagents market is expected to grow at a CAGR of 5.6% from 2020 to 2027 to reach USD 6.32 billion by 2027.

Succeeding an extensive secondary and primary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, trends, and opportunities. Increasing proteomics and genomics research studies, increasing funding for research activities, and growing industry-academia collaborations are the main driving factors. Furthermore, factors such as rising demand for protein therapeutics & personalized medicine, increasing investment in stem cell research, and rising need for biomarker identification represent high-growth opportunities for players during the forecast period. However, factors such as high cost and time related to identifying and developing potential antibodies are expected to hinder the growth of this market.

In 2020, based on type, the antibodies segment is projected to account for the largest share of this market. The large share of this segment is mainly attributed to increasing demand for antibodies for biomedical research, growing focus on protein and cell-based research, and increasing number of biomarker discovery.

On the basis of technology, in 2020, the flow cytometry segment is poised to command the largest share of the research antibodies and reagents market. The raising biomedical research for better diagnosis and therapy, initiatives for rising biomarker discovery, and growing cell & molecular-based research are the factors driving this growth of this segment.

In 2020, the proteomics segment is expected to command the largest share of the research antibodies and reagents market. Growing focus on protein-based research and the rising need for effective drugs using various protein-based disease profiling are the factors driving the growth of this segment.

The pharmaceutical and biotechnology industry is widely adopting research antibodies and reagents for proteomics research and drug discovery and development.

An in-depth analysis of the geographical scenario of the research antibodies and reagents market provides detailed qualitative and quantitative insights for the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2020, North America is estimated to command the largest share of the research antibodies and reagents market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The key players operating in the research antibodies and reagents market are GE Healthcare (U.S.), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann La-Roche AG (Switzerland), Rockland Immunochemicals Inc. (U.S.), Johnson & Johnson (U.S.), Agilent Technologies, Inc. (U.S.), Eli Lily and Company (U.S.), Becton Dickinson and Company (U.S.), Danaher Corporation (U.S.), PerkinElmer, Inc. (U.S.), GenScript Biotech Corporation (U.S.), Lonza (Switzerland), Bio-Techne Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Teva Pharmaceutical Industries Limited (Israel), Santa Cruz Biotechnology, Inc. (U.S.), and BioLegend, Inc. (U.S.).

Scope of the report:

Research Antibodies and Reagents Market, by Product Type
  • Antibodies
  • Antibodies Market, by Type
  • Primary Antibody
  • Secondary Antibody
  • Antibodies Market, by Production Type
  • Monoclonal Antibody
  • Polyclonal Antibody
  • Antibody Fragments
  • Antibodies Market, by Source
  • Mouse
  • Rabbit
  • Others
  • Antibodies Market, by Research Area
  • Oncology
  • Infectious Diseases
  • Cardiovascular Disease
  • Immunology
  • Neurology
  • Stem Cell Research
  • Others
  • Reagents
  • Sample Preparation Reagents
  • Media and Serum
  • Stain and Dyes
  • Probes
  • Buffers
  • Solvents
  • Antibody Production Reagents
  • Enzymes
  • Proteins
  • Other Research Reagents
Research Antibodies and Reagents Market, by Technology
  • Western Blot
  • Immunofluorescence
  • Enzyme-Linked Immunosorbent Assay
  • Multiplex Immunosorbent Assay
  • Flow Cytometry
  • Immunohistochemistry
  • Immunoprecipitation (IP)
  • Others
Research Antibodies and Reagents Market, by Application
  • Proteomics
  • Drug Discovery and Development
  • Genomics
Research Antibodies and Reagents Market, by End User
  • Pharmaceutical and Biotechnology Industry
  • Academic and Research Institutes
  • Contract Research Organizations
Research Antibodies and Reagents Market, by Geography
  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe (RoE)
  • Asia Pacific
  • Japan
  • China
  • India
  • Rest of APAC (RoAPAC)
  • Latin America
  • Middle East & Africa
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • BioLegend Inc. (U.S.)
  • GE Healthcare (U.S.)
  • Johnson & Johnson (U.S.)
  • Lonza (Switzerland)
  • Merck KGaA (Germany)
  • PerkinElmer Inc. (U.S.)
1. Introduction
1.1. Market Ecosystem
1.1.1. Research Antibodies and Reagents Market
1.1.2. Research Antibodies and Reagents Market, by Product
1.2. Currency and Limitations
1.2.1. Currency
1.2.2. Limitations
1.3. Key Stakeholders

2. Research Methodology
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research

3. Executive Summary

4. Market insights
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.1.1. Rising Proteomics and Genomics Research Studies
4.2.1.2. Increase in the Funding for Research Activities
4.2.1.3. Growing Industry-Academia Collaboration
4.2.2. Restraint
4.2.2.1. High Cost and Time Related to Identification and Development of Potential Antibodies
4.2.3. Opportunities
4.2.3.1. Rising Demand for Protein Therapeutics and Personalized Medicines
4.2.3.2. Rising Investment and Focus on Stem-Cell Research
4.2.3.3. Rising Need for New Biomarker Identification
4.2.3.4. Significant Opportunities from Emerging Asia-Pacific and Latin-American Markets
4.2.4. Challenges
4.2.4.1. Issues Related to Quality and Stability of Research Antibodies
4.2.4.2. Intense Pricing Pressure on Leading Players

5. Research Antibodies and Reagents Market, by Product
5.1. Introduction
5.2. Antibodies
5.2.1. Antibodies Market, by Type
5.2.1.1. Primary Antibodies
5.2.1.2. Secondary Antibody
5.2.2. Antibodies Market, by Production Type
5.2.2.1. Monoclonal Antibody
5.2.2.2. Polyclonal Antibody
5.2.2.3. Antibody Fragments
5.2.3. Antibody Market, by Source
5.2.3.1. Mouse
5.2.3.2. Rabbit
5.2.3.3. Other Sources
5.2.4. Antibodies Market, by Research Area
5.2.4.1. Oncology
5.2.4.2. Infectious Diseases
5.2.4.3. Cardiovascular Disease
5.2.4.4. Immunology
5.2.4.5. Neurology
5.2.4.6. Stem Cell Research
5.2.4.7. Other Research Areas
5.3. Reagents
5.3.1. Sample Preparation Reagents
5.3.1.1. Media and Serum
5.3.1.2. Stains and Dyes
5.3.1.3. Probes
5.3.1.4. Buffers
5.3.1.5. Solvents
5.3.2. Antibody Production Reagents
5.3.2.1. Enzymes
5.3.2.2. Proteins
5.3.3. Other Research Reagents

6. Research Antibodies and Reagents Market, by Technology
6.1. Introduction
6.2. Flow Cytometry
6.3. Immunofluorescence
6.4. Enzyme-Linked Immunosorbent Assay
6.5. Immunoprecipitation (IP)
6.6. Multiplex Immunosorbent Assay
6.7. Immunohistochemistry
6.8. Western Blot
6.9. Other Technologies

7. Research Antibodies and Reagents Market, by Application
7.1. Introduction
7.2. Proteomics
7.3. Drug Discovery and Development
7.4. Genomics

8. Research Antibodies and Reagents Market, by End User
8.1. Introduction
8.2. Pharmaceutical and Biotechnology Industry
8.3. Academic and Research Institutes
8.4. Contract Research Organizations

9. Research Antibodies and Reagents Market, by Geography
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Rest of Asia-Pacific
9.5. Latin America
9.6. Middle East & Africa

10. Competitive Landscape
10.1. Introduction
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Market Share Analysis

11. Company Profiles
11.1. GE Healthcare
11.1.1. Business Overview
11.1.2. Financial Overview
11.1.3. Product Portfolio
11.2. Merck KGaA
11.2.1. Business Overview
11.2.2. Financial Overview
11.2.3. Product Portfolio
11.2.4. Strategic Developments
11.3. Thermo Fisher Scientific Inc.
11.3.1. Business Overview
11.3.2. Financial Overview
11.3.3. Product Portfolio
11.3.4. Strategic Developments
11.4. F. Hoffmann-La Roche Ltd
11.4.1. Business Overview
11.4.2. Financial Overview
11.4.3. Product Portfolio
11.5. Rockland Immunochemicals Inc.
11.5.1. Business Overview
11.5.2. Product Portfolio
11.6. Johnson & Johnson (J&J)
11.6.1. Business Overview
11.6.2. Financial Overview
11.6.3. Product Portfolio
11.7. Eli Lilly and Company
11.7.1. Business Overview
11.7.2. Financial Overview
11.7.3. Product Portfolio
11.8. Teva Pharmaceutical industries Limited
11.8.1. Business Overview
11.8.2. Financial Overview
11.8.3. Product Portfolio
11.8.4. Strategic Developments
11.9. Abcam Plc
11.9.1. Business Overview
11.9.2. Financial Overview
11.9.3. Product Portfolio
11.9.4. Strategic Developments
11.10. Agilent Technologies, Inc.
11.10.1. Business Overview
11.10.2. Financial Overview
11.10.3. Product Portfolio
11.11. Cell Signaling Technology, Inc.
11.11.1. Business Overview
11.11.2. Product Portfolio
11.11.3. Strategic Developments
11.12. Becton Dickinson and Company
11.12.1. Business Overview
11.12.2. Financial Overview
11.12.3. Product Portfolio
11.13. Danaher Corporation
11.13.1. Business Overview
11.13.2. Financial Overview
11.13.3. Product Portfolio
11.14. Lonza
11.14.1. Business Overview
11.14.2. Financial Overview
11.14.3. Product Portfolio
11.14.4. Strategic Development
11.15. PerkinElmer, Inc.
11.15.1. Business Overview
11.15.2. Financial Overview
11.15.3. Product Portfolio
11.15.4. Strategic Developments
11.16. GenScript Biotech Corporation
11.16.1. Business Overview
11.16.2. Financial Overview
11.16.3. Product Portfolio
11.16.4. Strategic Developments
11.17. Bio-Techne Corporation
11.17.1. Business Overview
11.17.2. Financial Overview
11.17.3. Product Portfolio
11.17.4. Strategic Developments
11.18. Bio-Rad Laboratories, Inc.
11.18.1. Business Overview
11.18.2. Financial Overview
11.18.3. Product Portfolio
11.18.4. Strategic Developments
11.19. Santa Cruz Biotechnology, Inc.
11.19.1. Business Overview
11.19.2. Product Portfolio
11.20. Biolegend, Inc.
11.20.1. Business Overview
11.20.2. Product Portfolio
11.20.3. Strategic Developments

12. Appendix
12.1. Questionnaire
12.2. Available Customization
Note: Product cover images may vary from those shown
  • GE Healthcare (U.S.)
  • Merck KGaA (Germany)
  • Thermo Fisher Scientific Inc. (U.S.)
  • F. Hoffmann La-Roche AG (Switzerland)
  • Rockland Immunochemicals Inc. (U.S.)
  • Johnson & Johnson (U.S.)
  • Agilent Technologies Inc. (U.S.)
  • Eli Lily and Company (U.S.)
  • Becton Dickinson and Company (U.S.)
  • Danaher Corporation (U.S.)
  • PerkinElmer Inc. (U.S.)
  • GenScript Biotech Corporation (U.S.)
  • Lonza (Switzerland)
  • Bio-Techne Corporation (U.S.)
  • Bio-Rad Laboratories Inc. (U.S.)
  • Teva Pharmaceutical Industries Limited (Israel)
  • Santa Cruz Biotechnology Inc. (U.S.)
  • BioLegend Inc. (U.S.)
Note: Product cover images may vary from those shown
Adroll
adroll